Your browser doesn't support javascript.
An important call: Suggestion of using IL-10 as therapeutic agent for COVID-19 with ARDS and other complications.
Shih, Li-Jane; Yang, Chun-Chun; Liao, Min-Tser; Lu, Kuo-Cheng; Hu, Wan-Chung; Lin, Chih-Pei.
  • Shih LJ; Department of Medical Laboratory, Taoyuan Armed Forces General Hospital, Taoyuan City, Taiwan.
  • Yang CC; Graduate Institute of Medical Science, National Defense Medical Center, Taipei City, Taiwan.
  • Liao MT; Department of Laboratory Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.
  • Lu KC; Department of Pediatrics, Taoyuan Armed Forces General Hospital, Taoyuan, Taiwan.
  • Hu WC; National Defense Medical Center, Department of Pediatrics, Tri-Service General Hospital, Taipei, Taiwan.
  • Lin CP; Division of Nephrology, Department of Medicine, Fu-Jen Catholic University Hospital, New Taipei City, Taiwan.
Virulence ; 14(1): 2190650, 2023 12.
Article in English | MEDLINE | ID: covidwho-2281159
ABSTRACT
The global coronavirus disease 2019 (COVID-19) pandemic has a detrimental impact on public health. COVID-19 usually manifests as pneumonia, which can progress into acute respiratory distress syndrome (ARDS) related to uncontrolled TH17 immune reaction. Currently, there is no effective therapeutic agent to manage COVID-19 with complications. The currently available anti-viral drug remdesivir has an effectiveness of 30% in SARS-CoV-2-induced severe complications. Thus, there is a need to identify effective agents to treat COVID-19 and the associated acute lung injury and other complications. The host immunological pathway against this virus typically involves the THαß immune response. THαß immunity is triggered by type 1 interferon and interleukin-27 (IL-27), and the main effector cells of the THαß immune response are IL10-CD4 T cells, CD8 T cells, NK cells, and IgG1-producing B cells. In particular, IL-10 exerts a potent immunomodulatory or anti-inflammatory effect and is an anti-fibrotic agent for pulmonary fibrosis. Concurrently, IL-10 can ameliorate acute lung injury or ARDS, especially those caused by viruses. Owing to its anti-viral activity and anti-pro-inflammatory effects, in this review, IL-10 is suggested as a possible treatment agent for COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Distress Syndrome / Acute Lung Injury / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Virulence Year: 2023 Document Type: Article Affiliation country: 21505594.2023.2190650

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Distress Syndrome / Acute Lung Injury / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Virulence Year: 2023 Document Type: Article Affiliation country: 21505594.2023.2190650